Gilead Sciences new drug keeps 56 percent of lymphoma trial patients alive Ruby Khatun Khatun11 Dec 2017 10:30 AM ISTMore than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a...